These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 26675317)

  • 1. Assessment of Estradiol Response after Depot Triptorelin Administration in Girls with Central Precocious Puberty.
    Freire AV; Gryngarten MG; Ballerini MG; Arcari AJ; Escobar ME; Bergadá I; Ropelato MG
    Horm Res Paediatr; 2016; 85(1):58-64. PubMed ID: 26675317
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of Triptorelin 3-Month Depot Compared to 1-Month Depot for the Treatment of Korean Girls with Central Precocious Puberty in Single Tertiary Center.
    Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    J Korean Med Sci; 2021 Aug; 36(34):e219. PubMed ID: 34463062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Central precocious puberty: a single blood sample after gonadotropin-releasing hormone agonist administration in monitoring treatment.
    Salerno M; Di Maio S; Gasparini N; Mariano A; Macchia V; Tenore A
    Horm Res; 1998; 50(4):205-11. PubMed ID: 9838241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of triptorelin 6-month formulation in patients with central precocious puberty.
    Klein K; Yang J; Aisenberg J; Wright N; Kaplowitz P; Lahlou N; Linares J; Lundström E; Purcea D; Cassorla F
    J Pediatr Endocrinol Metab; 2016 Nov; 29(11):1241-1248. PubMed ID: 26887034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month sustained-release triptorelin (11.25 mg) in the treatment of central precocious puberty.
    Carel JC; Blumberg J; Seymour C; Adamsbaum C; Lahlou N;
    Eur J Endocrinol; 2006 Jan; 154(1):119-24. PubMed ID: 16382000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triptorelin stimulated luteinizing hormone concentrations for diagnosing central precocious puberty: study of diagnostic accuracy.
    Vukovic R; Milenkovic T; Soldatovic I; Pekic S; Mitrovic K; Todorovic S
    Endocrine; 2022 Mar; 75(3):934-941. PubMed ID: 34826116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of subcutaneous administration of gonadotropin-releasing hormone agonist on idiopathic central precocious puberty.
    Liang Y; Wei H; Zhang J; Hou L; Luo X
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(5):558-61. PubMed ID: 17219967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of 6-month triptorelin formulation on predicted adult height and basal gonadotropin levels in patients with central precocious puberty.
    Yoo E; Kim S; Jung HL; Shim JY; Shim JW; Kim DS; Kwak JH; Kim ES; Yang A
    Front Endocrinol (Lausanne); 2023; 14():1134977. PubMed ID: 36875449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Triptorelin 3-Month Formulation in Chinese Children with Central Precocious Puberty: A Phase 3, Open-Label, Single-Arm Study.
    Luo X; Zhang C; Yang Y; Xu X; Cheng X; Wei H; Wang L; Huang F; Shi X; Cabri P
    Adv Ther; 2023 Oct; 40(10):4574-4588. PubMed ID: 37584898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical study of subcutaneous administration of gonadotropin-releasing hormone agonist every six weeks in girls with idiopathic central precocious puberty].
    Liang Y; Wei H; Zhang JL; Hou L; Luo XP
    Zhonghua Er Ke Za Zhi; 2004 Nov; 42(11):845-9. PubMed ID: 15631714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High diagnostic accuracy of subcutaneous Triptorelin test compared with GnRH test for diagnosing central precocious puberty in girls.
    Freire AV; Escobar ME; Gryngarten MG; Arcari AJ; Ballerini MG; Bergadá I; Ropelato MG
    Clin Endocrinol (Oxf); 2013 Mar; 78(3):398-404. PubMed ID: 22845185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of basal LH in monitoring central precocious puberty treatment in girls.
    Calcaterra V; De Filippo G; Albertini R; Rendina D; Messini B; Monti CM; Bozzola E; Villani A; Bozzola M
    J Pediatr Endocrinol Metab; 2021 Jan; 34(1):45-50. PubMed ID: 33189082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Triptorelin depot stimulation test for central precocious puberty.
    Strich D; Kvatinsky N; Hirsch HJ; Gillis D
    J Pediatr Endocrinol Metab; 2013; 26(7-8):631-4. PubMed ID: 23425599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation.
    Martínez-Aguayo A; Hernández MI; Beas F; Iñiguez G; Avila A; Sovino H; Bravo E; Cassorla F
    J Pediatr Endocrinol Metab; 2006 Aug; 19(8):963-70. PubMed ID: 16995580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central precocious puberty in girls: Diagnostic study and auxological response to triptorelin treatment.
    Durá-Travé T; Ortega Pérez M; Ahmed-Mohamed L; Moreno-González P; Chueca Guindulain MJ; Berrade-Zubiri S
    Endocrinol Diabetes Nutr (Engl Ed); 2019; 66(7):410-416. PubMed ID: 30808564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A 6-Month Trial of the Efficacy and Safety of Triptorelin Pamoate (11.25 mg) Every 3 Months in Children with Precocious Puberty: A Retrospective Comparison with Triptorelin Acetate.
    Zenaty D; Blumberg J; Liyanage N; Jacqz-Aigrain E; Lahlou N; Carel JC;
    Horm Res Paediatr; 2016; 86(3):188-195. PubMed ID: 27603324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.